2025-12-28 - Analysis Report
Here's a report analyzing Schrodinger Inc. (SDGR) based on the data provided:

**Company Overview:** Schrodinger Inc. is a company that develops software for drug discovery and materials science.

**1) Return Rate Comparison:**

*   **SDGR Cumulative Return:** -54.34%
*   **VOO (S&P 500) Cumulative Return:** 71.37%
*   **Divergence:** -125.0 (Relative Divergence: 1.2)

**Analysis:** SDGR has significantly underperformed the S&P 500 (VOO) over the period examined. The negative divergence of -125.0 indicates a substantial difference in performance, and the relative divergence of 1.2 suggests the current difference is near the lower end of the observed fluctuation range between the two investments.

**Alpha, Beta Analysis:**

| Year       | CAGR  | MDD  | Alpha | Beta | Cap(B) |
|------------|-------|------|-------|------|--------|
| 2020-2022  | -70.0% | 78.2% | -76.0% | 0.0 | 1.4    |
| 2021-2023  | -57.0% | 81.0% | -59.0% | -0.0 | 2.6    |
| 2022-2024  | 6.0%  | 81.0% | -14.0% | -0.0 | 1.4    |
| 2023-2025  | -3.0% | 82.6% | -70.0% | -0.0 | 1.4    |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate has been negative for most periods, indicating a decline in investment value over time.
*   **MDD:** The Maximum Drawdown is consistently high, demonstrating significant potential for loss.
*   **Alpha:** The negative Alpha suggests that SDGR has underperformed its benchmark even when adjusted for risk.
*   **Beta:** The Beta values close to 0.0 indicates that SDGR's price is relatively independent of the overall market movements (S&P 500).
*   **Cap(B):** Market capitalization in billions of dollars.

**2) Recent Stock Price Fluctuations:**

*   **Current Price:** 18.31
*   **Previous Close:** 18.38
*   **Change:** -0.38
*   **5-day SMA:** 18.51
*   **20-day SMA:** 17.8955
*   **60-day SMA:** 18.9508

**Analysis:** The current price is slightly lower than the previous close. The 5-day SMA is above the 20-day SMA, suggesting a potential short-term upward trend. However, the 60-day SMA is higher than both, indicating a longer-term downward trend.

**3) Indicators Analysis:**

*   **MRI (Market Risk Indicator):** 1.0 (High Investment Recommended) - **Conflicting Signal:** This is a contrarian indicator, suggesting a potential buying opportunity because of high risk perception.  However, given the other data, this should be treated with extreme caution.
*   **RSI (Relative Strength Index):** 56.69 - Indicates neutral to slightly bullish momentum.
*   **PPO (Percentage Price Oscillator):** 0.839 - Suggests positive momentum, but the value is relatively low.
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (58 shares - Very Safe - MRI:0.90) Monthly invest 1.4% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent Divergence Change:** -0.7 (Negative) - Indicates a short-term downward trend relative to the comparison asset (S&P 500).
*   **Expected Return (%):** -5407.7% -  This is an extremely negative expected return, indicating significant concerns about the stock's future performance relative to its current price.
*   **Fluctuation Issue:** The small price change of -0.38, suggests that there is not sharp rebound, sharp decline issues.

**4) Recent News & Significant Events:**

*   **Positive Sentiment Articles:** Several articles suggest buying opportunities ("Buy the Bottom," "Trading Up," "Unlocking Hidden Value"), while others discuss valuation and strategic shifts.
*   **Mixed Signals:**  Quiver Quantitative notes a price increase on a specific day, but overall, the news provides a mixed view, with some optimism offset by valuation concerns.

**4-2) Analyst Opinions:**

*   **Consensus:** Strong Buy (Mean: 1.44)
*   **Target Price:** Avg: 27.22, High: 33.00, Low: 18.00
*   **Recent Rating Changes:**  (No specific changes provided, but assumed to be relatively stable).

**Analysis:** Despite the poor performance, analyst consensus remains positive. However, the low target price is near the current price (18.31).

**5) Recent Earnings Analysis:**

| Date       | EPS   | Revenue  |
|------------|-------|----------|
| 2025-11-05 | -0.45 | 0.05 B$  |
| 2025-08-06 | -0.59 | 0.05 B$  |
| 2025-05-07 | -0.82 | 0.06 B$  |
| 2024-11-12 | -0.52 | 0.04 B$  |
| 2025-11-05 | -0.52 | 0.04 B$  |

**Analysis:** The company is consistently reporting negative EPS, and revenue is relatively stable but low.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-09-30   | $0.05B  | 51.61%        |
| 2025-06-30   | $0.05B  | 47.77%        |
| 2025-03-31   | $0.06B  | 52.26%        |
| 2024-12-31   | $0.09B  | 72.61%        |
| 2024-09-30   | $0.04B  | 50.24%        |

**Capital and Profitability:**

| Quarter      | Equity | ROE      |
|--------------|--------|----------|
| 2025-09-30   | $0.32B | -10.21%  |
| 2025-06-30   | $0.34B | -12.59%  |
| 2025-03-31   | $0.37B | -16.01%  |
| 2024-12-31   | $0.42B | -9.54%   |
| 2024-09-30   | $0.45B | -8.49%   |

**Analysis:**

*   **Revenue:** Revenue is relatively consistent but low.
*   **Profit Margin:** High profit margins indicate strong pricing power or cost control on the revenue generated.
*   **Equity:** Equity is declining, suggesting the company is burning through cash.
*   **ROE:** Negative ROE confirms the company is not generating returns for shareholders.

**7) Comprehensive Analysis (Summary):**

Schrodinger Inc. (SDGR) presents a mixed picture.

*   **Negative Performance:** It has significantly underperformed the S&P 500.
*   **High Risk:** High Maximum Drawdown and negative Alpha demonstrate substantial risk.
*   **Negative Financials:** Negative EPS and declining equity are concerning.
*   **Analyst Optimism vs. Reality:**  Analysts have a "Strong Buy" consensus, but the target price is not far from the current price and is in complete conflict with data.
*   **Recent News:** Recent news articles are mixed.
*   **MRI Signal:** MRI shows high investment recommended, but should be ignored.

**Conclusion:** While some indicators suggest a potential buying opportunity due to perceived undervaluation and positive analyst sentiment, the underlying financials and past performance raise significant concerns.  A potential investor should be extremely cautious and conduct thorough due diligence before investing in SDGR. The extremely negative expected return is a serious red flag. It is also important to understand the potential reasons for the divergence between analyst expectations and historical performance.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.